AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32223601
Drug: Targeted Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted Medication Therapy Management (tMTM) intervention
Trial: 33734000
Drug: Repetitive Transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) and Bright Light Therapy (BLT)
Trial: 33392885
Drug: Positive anti‐β2‐GPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive anti‐β2‐GPI antibody
Trial: 33392885
Drug: Negative anti‐β2‐GPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative anti‐β2‐GPI antibody
Trial: 32776518
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy with closed mouth
Trial: 32776518
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy with open mouth
Trial: 35506888
Drug: Paediatric Autism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric Autism Communication Therapy (PACT) - 12 sessions
Trial: 36191485
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tea polyphenols (TP)
Trial: 36191485
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tea polyphenols (TP)
Trial: 36191485
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tea polyphenols (TP)
Trial: 34274136
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m2 plus prednisone and granulocyte colony-stimulating factor)
Trial: 33449432
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training intervention supporting home oral hygiene and dental visits
Trial: 34779349
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (1 year of 150 min weekly combined strength and endurance exercise)
Trial: 33517741
Drug: US-guided injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided injection
Trial: 33191260
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 650 mg
Trial: 35331943
Drug: smartphone App
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: smartphone App delivery of caregiver skills with Mentalizing Imagery Therapy (MIT)
Trial: 33811034
Drug: Subcutaneous denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous denosumab 60 mg every 6 months for 24 months
Trial: 36064438
Drug: AutoKinetics dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AutoKinetics dosing for other antibiotics (meropenem, vancomycin, ceftriaxone)
Trial: 36064438
Drug: AutoKinetics dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AutoKinetics dosing and Standard dosing (Control)
Trial: 36064438
Drug: Higher dosing
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosing (AutoKinetics)
Trial: 35104279
Drug: Aspirin 80
RxNorm normalized name: aspirin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 80 mg daily
Trial: 33025656
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg for 1 year
Trial: 33025656
Drug: LDL levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL levels more than 90 mg/dl in the first year
Trial: 33025656
Drug: LDL levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL levels less than 90 mg/dl in the first year
Trial: 33048462
Drug: NobelReplace Tapered
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NobelReplace Tapered implants (Nobel Biocare, Sweden)
Trial: 33048462
Drug: NobelSpeedy implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NobelSpeedy implants (Nobel Biocare, Sweden)
Trial: 34246130
Drug: Methacholine challenge
RxNorm normalized name: Methacholine Challenge Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine challenge test (MCT) with doses of PC20 ? 8 mg/ml
Trial: 34246130
Drug: Methacholine challenge
RxNorm normalized name: Methacholine Challenge Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine challenge test (MCT) with doses of PC20 ? 2 mg/ml
Trial: 34246130
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of asthmatic wheeze and BHR
Trial: 36111910
Drug: Concurrent aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic and resistance exercises (three sessions per week for twelve weeks on alternative days)
Trial: 36111910
Drug: Regular lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular lifestyle practices and medical treatment without any exercise intervention
Trial: 33775175
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual control
Trial: 34223660
Drug: CBD 200
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 200 mg
Trial: 34223660
Drug: CBD 800
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD 800 mg
Trial: 35776835
Drug: Tapentadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (50 mg extended-release tablets)
Trial: 36099926
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg, intravenous, once every 3 weeks for 16 cycles or 1 year)
Trial: 36099926
Drug: Placebo (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous, once every 3 weeks for 16 cycles or 1 year)
Trial: 34144032
Drug: High-dose Erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Erythropoietin for Asphyxia and Encephalopathy Trial
Trial: 32921425
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (MEL) therapy as an add-on treatment, 2 to 10 mg, for a long period.
Trial: 32921425
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (MEL) therapy, 2 mg slow release, 1 to 2 hours before bedtime, for 3 to 12 weeks.
Trial: 32921425
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy used 12 hours before melatonin treatment.
Trial: 35578445
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of tofogliflozin (20 mg) and pioglitazone (15–30 mg)
Trial: 32648392
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (estazolam 1-2 mg per night for 4 weeks)
Trial: 32211798
Drug: Milk8 (8.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk8 (8.8 g milk protein/d, 100 kcal/d)
Trial: 32211798
Drug: Milk/rice (4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk/rice (4.4 g milk and 4.4 g rice protein/d, 100 kcal/d)
Trial: 32211798
Drug: Milk4 (4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk4 (4.4 g milk protein/d, 48 kcal/d)
Trial: 34370858
Drug: Ultra-long downregulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-long downregulation with GnRH agonist (triptorelin depot) for at least 3 months followed by ART stimulation.
Trial: 34370858
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group underwent ART stimulation in a classical long agonist protocol using oral contraceptives.
Trial: 32443343
Drug: Twice-weekly MHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly MHD
Trial: 32443343
Drug: 3-times-weekly MHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-times-weekly MHD
Trial: 34346046
Drug: Duloxetine 20mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20mg/daily
Trial: 34346046
Drug: Solifenacin 10mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 10mg/daily
Trial: 35346339
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy for a minimum of 16 hours immediately post extubation
Trial: 35346339
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy for a minimum of 16 hours immediately post extubation
Trial: 35346339
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy
Trial: 33662489
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intermittent vitamin D3 supplementation
Trial: 33662489
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose B12 supplementation
Trial: 34740538
Drug: L-Carnitine 50
RxNorm normalized name: L-Carnitine 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine 50 mg/kg
Trial: 32818963
Drug: VT‐1161 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 300 mg once daily for 3 days
Trial: 32818963
Drug: VT‐1161 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 600 mg once daily for 3 days
Trial: 32818963
Drug: VT‐1161 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT‐1161 600 mg twice daily for 3 days
Trial: 32818963
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg (single dose)
Trial: 32929891
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg, 3 times per week for 16 weeks
Trial: 32929891
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg, 3 times per week for 16 weeks (in AERD-negative patients)
Trial: 35236423
Drug: Low-fat milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat milk fortified with 1500 IU nano-encapsulated vitamin D3 (200 mL/day)
Trial: 35236423
Drug: Low-fat yogurt
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D3 (150 g/day)
Trial: 35236423
Drug: Simple milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple milk (200 mL/day)
Trial: 35236423
Drug: Simple yogurt
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple yogurt (150 g/day)
Trial: 32494991
Drug: Pharmacist-administered deprescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-administered deprescribing intervention
Trial: 33905144
Drug: Subcutaneous nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nerve field stimulation in combination with optimized medical management
Trial: 33894725
Drug: Reduning injection
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduning injection (20 mL/day for 14 days)
Trial: 33894725
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine treatment without Reduning injection)
Trial: 33894725
Drug: Reduning injection
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduning injection
Trial: 33764833
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg or 100 mg of water-soluble CoQ10 (total daily dose, 100 mg [n = 5] or 200 mg [6])
Trial: 34642106
Drug: Thought Field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thought Field Therapy (single session)
Trial: 34861430
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d) and Vitamin D (1000 IU/d) supplementation
Trial: 34793441
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg iOWH032 every 8 hours for 3 days
Trial: 34089515
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with erythrosine, 15 min incubation, 15 min continuous light irradiation
Trial: 34089515
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with erythrosine, 2 min incubation, 15 min continuous light irradiation
Trial: 34089515
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with erythrosine, 15 min incubation, fractionated light (5 x 30 sec)
Trial: 34089515
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with erythrosine, 2 min incubation, fractionated light (5 x 30 sec)
Trial: 33993346
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 1 µg/kg dexmedetomidine (DEX) diluted in 4 mL 0.9% saline twice daily
Trial: 33993346
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 4 mL 0.9% saline
Trial: 34752934
Drug: Accelerated intermittent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated intermittent theta-burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days
Trial: 34337507
Drug: Intravesical HA/CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical HA/CS plus an oral formulation of curcumin, quercetin, HA, and CS (group A)
Trial: 35406085
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral nutritional supplement (ONS)
Trial: 34224214
Drug: Fexofenadine-montelukast fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine-montelukast fixed-dose combination tablet (120 mg fexofenadine and 10 mg montelukast)
Trial: 33627186
Drug: Integrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative therapy based on Ayurveda and Yoga
Trial: 33627186
Drug: Modern western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern western medicine (MWM)
Trial: 33861657
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg three times a day
Trial: 35441854
Drug: Local estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local estradiol (twice weekly estradiol cream from delivery through 3 months postpartum)
Trial: 35441854
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (twice weekly from delivery through 3 months postpartum)
Trial: 32013913
Drug: Intravitreal conbercept
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal conbercept (IVC) injection at the end of pars plana vitrectomy
Trial: 32013913
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IVC injection)
Trial: 32013913
Drug: Intravitreal conbercept
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal conbercept (IVC) injection
Trial: 34009790
Drug: Head and
RxNorm normalized name: Head and Shoulders
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head and neck cooling treatment applied at postinjury assessment visit and at 72 hours post-injury
Trial: 34009790
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (short term brain rest)
Trial: 34180719
Drug: MSCs transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCs transplantation therapy (3 × 10^6 cells/kg, intravenously) on treatment days 0, 3, and 6
Trial: 34180719
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group 1 and Group 2)
Trial: 34180719
Drug: MSCs transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSCs transplantation therapy (Group 3)
Trial: 32111302
Drug: 0.069 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.069 mg/kg 25-Hydroxycholecalciferol (25-OH-D3) in NRC vitamin premix
Trial: 32111302
Drug: 0.069 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.069 mg/kg 25-Hydroxycholecalciferol (25-OH-D3) in standard nutrient density diet with NRC vitamin premix
Trial: 35971137
Drug: 10 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sessions of symptom-specific CBT-VR plus treatment as usual
Trial: 35971137
Drug: 10 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sessions of standard symptom-specific CBT for paranoid ideations (CBT) plus treatment as usual
Trial: 35962688
Drug: Low-volume Ringer's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume Ringer's solution infusion
Trial: 34842533
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (KAD_SCL_01)
Trial: 36432449
Drug: Two-year intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-year intervention based on the Mediterranean diet including group nutritional education, individualized dietary treatment, and physical activity program
Trial: 34660639
Drug: Latent MTrPs
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latent MTrPs injection
Trial: 34919104
Drug: Nutraceutical containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical containing 3 g d‐1 or 5 g d‐1 doses of 35% or 70% BG with 600 mg d‐1 of GCBE
Trial: 34919104
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g - 70% BG
Trial: 32007207
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg plus standard antiemetic therapy
Trial: 32007207
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard antiemetic therapy
Trial: 34974824
Drug: DoIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DoIT performed once weekly (DoIT-1, n=24)
Trial: 34974824
Drug: DoIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DoIT performed twice weekly (DoIT-2, n=23)
Trial: 34974824
Drug: DoIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DoIT performed thrice weekly (DoIT-3, n=21)
Trial: 33396972
Drug: 3.2 g
RxNorm normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g bovine colostrum orally twice a day for 24 weeks
Trial: 35279470
Drug: Metformin users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin users (327 patients with DM)
Trial: 35279470
Drug: Non-metformin users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-metformin users (294 patients with DM)
Trial: 33980057
Drug: Decision Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision Aid Tool (DAT) for LT4 dosage adjustment
Trial: 33594986
Drug: Oral 200.000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 200.000 IU Cholecalciferol per month
Trial: 35410145
Drug: Modified comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified comprehensive geriatric assessment and monthly standardized case conferencing
Trial: 35524357
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) 60 IU/kg twice weekly for 52 weeks
Trial: 34216524
Drug: Intensive-therapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive-therapy group
Trial: 36818484
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (0.5 µg/kg)